HUMA
Humacyte, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:D+
Company Profile
CEO
Laura E. Niklason
IPO Date
2020-12-01
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Humacyte, Inc.
CEO
Laura E. Niklason
IPO Date
2020-12-01
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 80,000 |
| $1.08 |
| 12 Jun 2026 | Wallace Max N. | director | A-Award | Acquired | 80,000 | $1.08 |
| 12 Jun 2026 | Niklason Laura E | director, officer: President, CEO and Director | A-Award | Acquired | 80,000 | $1.08 |
| 12 Jun 2026 | Sebelius Kathleen | director | A-Award | Acquired | 80,000 | $1.08 |
| 12 Jun 2026 | Jones Keith Anthony | director | A-Award | Acquired | 80,000 | $1.08 |
| 12 Jun 2026 | Green Charles Bruce | director | A-Award | Acquired | 80,000 | $1.08 |
| 12 Jun 2026 | Seimetz Diane | director | A-Award | Acquired | 80,000 | $1.08 |
| 12 Jun 2026 | Bamforth John Philip | director | A-Award | Acquired | 80,000 | $1.08 |
| 12 Jun 2026 | Brown Emery N. | director | A-Award | Acquired | 80,000 | $1.08 |
| $1,001 - $15,000 |
| 13 Jun 2024 | Tommy Tuberville | Tommy Tuberville | Sale (Partial) | $15,001 - $50,000 |
| 15 May 2024 | Tommy Tuberville | Tommy Tuberville | Sale (Partial) | $50,001 - $100,000 |
| 14 May 2024 | Tommy Tuberville | Tommy Tuberville | Sale (Partial) | $50,001 - $100,000 |
| 15 Apr 2024 | Tommy Tuberville | Tommy Tuberville | Purchase | $15,001 - $50,000 |
| 14 Apr 2024 | Tommy Tuberville | Tommy Tuberville | Purchase | $15,001 - $50,000 |
| 15 Mar 2024 | Tommy Tuberville | Tommy Tuberville | Purchase | $15,001 - $50,000 |
| 14 Mar 2024 | Tommy Tuberville | Tommy Tuberville | Purchase | $15,001 - $50,000 |